AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary
efficacy of AN0025 in combination with pembrolizumab in patients with locally
advanced/metastatic tumors. It will include a dose-limiting toxicity observation phase
followed by an expansion phase. All enrolled patients will be treated with AN0025 and
Pembrolizumab until the patient experiences disease progression, unacceptable toxicity or
withdraws consent, or for a maximum of 35 cycles (approximately 2 years). The dose of
pembrolizumab will remain constant at 200 mg every 3 weeks (Q3W) for each dose level of
AN0025 and in each cohort.